SG11201805184TA - Combination therapy - Google Patents
Combination therapyInfo
- Publication number
- SG11201805184TA SG11201805184TA SG11201805184TA SG11201805184TA SG11201805184TA SG 11201805184T A SG11201805184T A SG 11201805184TA SG 11201805184T A SG11201805184T A SG 11201805184TA SG 11201805184T A SG11201805184T A SG 11201805184TA SG 11201805184T A SG11201805184T A SG 11201805184TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- lochside
- alaninyl
- benzoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 11M1111101110101011111 HO 11111 011101011011110111111101110111110111011# International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/109486 Al 29 June 2017(29.06.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/7068 (2006.01) A61K 33/00 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/GB2016/054018 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: 21 December 2016 (21.12.2016) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PCT/GB2015/054158 (84) Designated States (unless otherwise indicated, for every 23 December 2015 (23.12.2015) GB 1609770.1 3 June 2016 (03.06.2016) GB kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: NUCANA BIOMED LIMITED [GB/GB]; 10 Lochside Place, Edinburgh Scotland EH12 9RG (GB). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventor: GRIFFITH, Hugh; c/o NuCana BioMed Lim- ited, 10 Lochside Place, Edinburgh EH12 9RG (GB). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (74) Agent: HGF LIMITED (LEEDS); 1 City Walk, Leeds LS11 9DX (GB). Published: — with international search report (Art. 21(3)) Il GC iv 01 0 1-1 IN 1-1 (54) Title: COMBINATION THERAPY 0 N (57) : This invention relates to a combination of gemcitabine-[phenyl-benzoxy-L-alaninyl)]- phosphate (chemical name: 2'- en. ) Deoxy-2',2'-difluoro-D-cytidine-5'-0-[phenyl (benzoxy- L- alaninyl)] phosphate) (NUC-1031) and a platinum-based anticancer agent selected from cisplatin, picoplatin, lipoplatin and triplatin. The combinations are useful in the treatment of cancer and particu - .,. laxly biliary tract and bladder cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2015/054158 WO2017109444A1 (en) | 2015-12-23 | 2015-12-23 | Combination therapy |
| GBGB1609770.1A GB201609770D0 (en) | 2016-06-03 | 2016-06-03 | Combination therapy |
| PCT/GB2016/054018 WO2017109486A1 (en) | 2015-12-23 | 2016-12-21 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805184TA true SG11201805184TA (en) | 2018-07-30 |
Family
ID=57681677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805184TA SG11201805184TA (en) | 2015-12-23 | 2016-12-21 | Combination therapy |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20190022117A1 (en) |
| EP (2) | EP3738595A1 (en) |
| JP (1) | JP6898329B2 (en) |
| KR (1) | KR20180096698A (en) |
| CN (1) | CN108697725A (en) |
| AU (1) | AU2016375861B2 (en) |
| CA (1) | CA3008749C (en) |
| CY (1) | CY1122835T1 (en) |
| DK (1) | DK3393478T3 (en) |
| EA (1) | EA037459B1 (en) |
| ES (1) | ES2778933T3 (en) |
| HK (1) | HK1255110A1 (en) |
| HR (1) | HRP20200423T1 (en) |
| HU (1) | HUE050290T2 (en) |
| IL (1) | IL260076A (en) |
| LT (1) | LT3393478T (en) |
| MA (1) | MA51576A (en) |
| MD (1) | MD3393478T2 (en) |
| ME (1) | ME03677B (en) |
| MX (1) | MX2018007772A (en) |
| MY (1) | MY194629A (en) |
| PH (1) | PH12018501339A1 (en) |
| PL (1) | PL3393478T3 (en) |
| PT (1) | PT3393478T (en) |
| RS (1) | RS60211B1 (en) |
| SG (1) | SG11201805184TA (en) |
| SI (1) | SI3393478T1 (en) |
| WO (1) | WO2017109486A1 (en) |
| ZA (1) | ZA201804155B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2891266C (en) | 2012-11-16 | 2020-12-08 | University College Cardiff Consultants Limited | Gemcitabine phosphate mixture for the treatment of cancer |
| SI3160978T1 (en) | 2014-06-25 | 2020-11-30 | NuCana plc | Gemcitabine prodrugs |
| TWI674097B (en) | 2014-06-25 | 2019-10-11 | 英商努卡那公眾有限公司 | Formulations of phosphate derivatives |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| CN108135920A (en) | 2015-10-05 | 2018-06-08 | 努卡那有限公司 | Combination treatment |
| US10774104B2 (en) | 2015-12-11 | 2020-09-15 | Laurus Labs Private Ltd | Diastereoselective synthesis of phosphate derivatives |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| EP2882419A4 (en) * | 2012-08-13 | 2016-05-18 | Regulon Inc | Methods for treatment of cancer using lipoplatin |
| WO2014078295A1 (en) * | 2012-11-13 | 2014-05-22 | BoYen Therapeutics, Inc. | Gemcitabine prodrugs and uses thereof |
| JP6761852B2 (en) * | 2015-05-14 | 2020-09-30 | ニューカナ パブリック リミテッド カンパニー | Cancer treatment |
| CN108135920A (en) * | 2015-10-05 | 2018-06-08 | 努卡那有限公司 | Combination treatment |
-
2016
- 2016-12-21 JP JP2018532746A patent/JP6898329B2/en active Active
- 2016-12-21 CN CN201680082464.9A patent/CN108697725A/en active Pending
- 2016-12-21 SI SI201630680T patent/SI3393478T1/en unknown
- 2016-12-21 ES ES16820005T patent/ES2778933T3/en active Active
- 2016-12-21 MX MX2018007772A patent/MX2018007772A/en unknown
- 2016-12-21 EP EP20160070.7A patent/EP3738595A1/en not_active Withdrawn
- 2016-12-21 PT PT168200053T patent/PT3393478T/en unknown
- 2016-12-21 DK DK16820005.3T patent/DK3393478T3/en active
- 2016-12-21 MD MDE20181039T patent/MD3393478T2/en unknown
- 2016-12-21 KR KR1020187020533A patent/KR20180096698A/en not_active Application Discontinuation
- 2016-12-21 CA CA3008749A patent/CA3008749C/en active Active
- 2016-12-21 RS RS20200297A patent/RS60211B1/en unknown
- 2016-12-21 PL PL16820005T patent/PL3393478T3/en unknown
- 2016-12-21 LT LTEP16820005.3T patent/LT3393478T/en unknown
- 2016-12-21 WO PCT/GB2016/054018 patent/WO2017109486A1/en active Application Filing
- 2016-12-21 HU HUE16820005A patent/HUE050290T2/en unknown
- 2016-12-21 SG SG11201805184TA patent/SG11201805184TA/en unknown
- 2016-12-21 MA MA051576A patent/MA51576A/en unknown
- 2016-12-21 EP EP16820005.3A patent/EP3393478B1/en active Active
- 2016-12-21 US US16/065,498 patent/US20190022117A1/en not_active Abandoned
- 2016-12-21 AU AU2016375861A patent/AU2016375861B2/en active Active
- 2016-12-21 ME MEP-2020-56A patent/ME03677B/en unknown
- 2016-12-21 EA EA201891473A patent/EA037459B1/en unknown
- 2016-12-21 MY MYPI2018001015A patent/MY194629A/en unknown
-
2018
- 2018-06-17 IL IL260076A patent/IL260076A/en unknown
- 2018-06-21 PH PH12018501339A patent/PH12018501339A1/en unknown
- 2018-06-21 ZA ZA2018/04155A patent/ZA201804155B/en unknown
- 2018-11-08 HK HK18114265.9A patent/HK1255110A1/en unknown
-
2020
- 2020-03-16 HR HRP20200423TT patent/HRP20200423T1/en unknown
- 2020-03-17 CY CY20201100245T patent/CY1122835T1/en unknown
-
2022
- 2022-06-21 US US17/845,878 patent/US20230149436A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805184TA (en) | Combination therapy | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201803905RA (en) | A hair styling appliance | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201901841TA (en) | Targeting ligands | |
| SG11201803728YA (en) | Topical pharmaceutical formulations for treating inflammatory-related conditions | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201810018TA (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201803951QA (en) | Oligonucleotides for inducing paternal ube3a expression | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201810196RA (en) | Cancer treatments | |
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201805318SA (en) | Formulations of phosphoramidate derivatives of nucleoside drugs |